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Abstract The bipartite repressor elements, termed cell cycle-
dependent element (CDE)/cell cycle regulatory element (CCRE)-
cell cycle homology region (CHR) control the growth-dependent
transcription of the cyclin A, cdc25C, cdc2 genes. Here, we have
identified a functional element displaying the signature of the
CDE^CHR in the promoter of the mouse RB2 (p130) gene,
encoding the retinoblastoma protein family (pRB)-related protein
p130. This element locates close to the major transcription start
site where it makes major groove contacts with proteins that can
be detected in a cellular context using in vivo genomic
footprinting techniques. Inactivation of either the CDE or
CHR sequence strongly up-regulates the p130 promoter activity
in exponentially growing cells, a situation where endogenous
p130 gene expression is almost undetectable. Electrophoretic
mobility shift assays suggest that two different protein complexes
bind independently to the p130 CDE and CHR elements, and
that the protein(s) bound to the CDE might be related to those
bound on cyclin A and cdc2 promoters.
z 2000 Federation of European Biochemical Societies.
Key words: Retinoblastoma protein family; p130;
Cell cycle-dependent element; Cell cycle homology region;
Promoter; Transcriptional repression
1. Introduction
The orderly progression through the mammalian cell cycle
is controlled, at least in part, by the level of expression of
genes encoding rate-limiting regulators of cell proliferation,
including members of the cell cycle ‘machinery’ such as cy-
clins, cdks, cdk’s inhibitors or various regulators of transcrip-
tion such as E2F, retinoblastoma protein family (pRB),
B-myb, c-myc, etc. Although multiple positive transcriptional
events are undoubtedly involved in the coordinated activation
of these genes, there is now increasing evidence that the pro-
moters of several of them contains a phase speci¢c and dom-
inant repressor element located in the transcription start site
region and whose function is to ensure the correct timing and/
or level of expression of those genes [1^4]. One of these cell
cycle-regulated negative elements, termed cell cycle-dependent
element (CDE)/cell cycle regulatory element (CCRE)-cell cycle
homology region (CHR), has been shown to be important for
the cell cycle-dependent expression of both the cyclin A and
cdc25C genes and possibly the cdc2, b-myb, survivin and Plk
(polo-like kinase) genes [2,5^12]. In the promoter of these
genes, the CHR (5P-A/TG/TGAA-3P) is cooperating with a
contiguous GC-rich motif (5P-G/CGCGG-3P), termed CDE
or CCRE, to form a bipartite cell cycle-regulated repressor
element. Inactivation of either region of this two-components
module results in high constitutive transcriptional activity of
these promoters throughout the cell cycle [2,5,7,9,11].
Searching for novel examples of CDE/CHR-like sequences
in the transcription start site region of genes encoding cell
cycle regulators, we now report the cloning of the promoter
of the mouse p130 gene encoding the pRB-related protein
p130, within which we have identi¢ed and characterized a
functional CDE/CHR-like regulatory element.
Members of pRB (p107 and p130) are key signal trans-
ducers connecting the cell cycle machinery to the transcrip-
tional control of genes whose products regulate cell growth
and di¡erentiation processes [1,3,13]. Their cellular function
depends on their ability to bind to and modulate the activity
of various transcription factors [1,3]. Most studies on p130
have focused on its interaction with the E2F/DP family of
transcription factors [1,3,13]. The hypophosphorylated form
of p130 interacts with E2F/DP bound to DNA, acting either
as a sequestrating factor by blocking the transactivating do-
main of E2Fs or as a co-repressor by recruiting histone de-
acetylases factors [1,3,13,14]. E2F complexes containing p130
predominate in the G0 state of many di¡erentiated cells and
tissues where they are thought to play a major role in the
maintenance of the quiescent state of the cells [1,3,13,15,16].
Indeed, E2F^p130 complexes are believed to function by re-
pressing the expression of genes that are required for G0/G1-
S-phase progression and DNA biosynthesis, a process which
is critical for cell cycle exit and terminal di¡erentiation
[1,3,13]. Consistent with this, p130 proteins and E2F com-
plexes containing p130 are almost undetectable in exponen-
tially growing ¢broblasts [1,3,13^16].
Here we show that the promoter of the mouse p130 gene
contains a CDE/CHR-like sequence located nearby its major
transcription initiation site. This sequence is likely to represent
a CDE/CHR-like functional repressor element active in grow-
ing cells since, (i) it is occupied in vivo by proteins, (ii) muta-
tion of either the CDE or the CHR sequence leads to a strong
up-regulation of the p130 promoter activity in proliferating
cells, a situation where endogenous p130 gene expression is
almost undetectable, (iii) it binds protein complexes that
might be related to the unidenti¢ed protein(s) bound on the
CDEs of p130, cyclin A and cdc2 genes.
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2. Materials and methods
2.1. Cell culture, synchronization
Swiss 3T3 and NIH 3T3 ¢broblasts were grown at 37‡C in a 5%
CO2-containing atmosphere, in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) (Gibco) supplemented with 10% (v/v) fetal calf serum (FCS)
(Biomedia). Relative luciferase activities of the the wild-type and
CDE^CHR mutant p130 promoter-luciferase constructs in cells
synchronized in G0 or at the G1/S or G2-M boundaries. For synchro-
nization, cells were treated 18 h with 0.5 mM hydroxyurea to block at
the G1/S transition or with 0.1 Wg/ml Nocodazole to block in G2-M
(prometaphase) or serum-starved at con£uence during 18 h to block
in G0. Cells were then harvested and assayed for luciferase and L-
galactosidase activities. Diagram is showing the average of two inde-
pendent experiments.
2.2. RNA isolation and primer extension
Total cellular RNA was prepared by guanidinium thyocyanate^
phenol/chloroform extraction according to standard protocols. For
primer extension, the oligonucleotide mp130-2 with sequence 5P-GCT-
GGAGGAGGCGGTGGCGACTGGTTG-3P was 32P-labelled with
T4-polynucleotide kinase (Amersham) to a speci¢c activity of 107
dpm/50 ng and puri¢ed by gel electrophoresis. Primer extension anal-
ysis was performed according to standard protocols using 10 Wg of
total RNA, 105 dpm of radiolabelled oligonucleotide and a mixture of
1.25 U AMV reverse transcriptase (Gibco, Life Technologies) and
100 U MMLV reverse transcriptase (Gibco, Life Technologies). To
identify the position of the transcription start site, the products of the
primer extension reaction were run alongside a G-speci¢c ladder of
the transcription start site region of the mouse p130 promoter which
had been generated by ligation mediated PCR ampli¢cation
(LMPCR) on in vitro DMS-methylated genomic DNA (see genomic
footprint protocols below) [4].
2.3. Isolation of the murine p130 promoter and analysis of promoter
activity
The murine p130 proximal promoter was cloned using the
Mouse Genome Walker kit from Clontech, according to the sup-
plier’s instructions using two nested oligos whose sequences were de-
rived from the published mouse p130 c-DNA sequence [17] : p130-1:
5P-CTCTTCCTCCGAGCTGGCTGCAGCAGC-3P and the nested
p130-2: 5P-GCTGGAGGAGGCGGTGGCGACTGGTTG-3P. A 350
bp PCR fragment was generated, end blunted, and cloned into the
luciferase-based reporter vector pGL3 (Promega). The resulting re-
porter construct, pGL3p130-300 was sequenced and used for func-
tional analyses after transfection. SOE-PCR performed with the
LF23 oligonucleotide (5P-GGGCGGGCGCTTCTAGATAGATCTG-
GCTGCGG-3P) was used to create mutations in both the CDE and
CHR sequences of the mp130 promoter using pGL3p130-300 as a
template. The same method was used to create speci¢c mutations in
either the CDE (LF24 5P-GGGCGGGCGCTTCTAGATTTGAAT-
GGCTGCGG-3P) or the CHR (LF25 5P-GGGCGGGCGCTTCGCG-
GTAGATCTGGCTGCGG-3P). The resulting vectors pGL3- p130-
300, pGL3p130-CDE/CHRmut, pGL3p130-CDEmut, or pGL3p130-
CHRmut were co-transfected into NIH3T3 cells together with the
L-galactosidase expression vector pCH110. Luciferase activity values
were normalized to the L-galactosidase activity to account for varia-
tions in transfection e⁄ciencies. Transfections, L-galactosidase and
luciferase assays were performed as described previously [4,18].
2.4. Electrophoretic mobility shift assays (EMSA)
Nuclear extracts from NIH 3T3 cells were prepared as previously
described [4,6]. All probes were 32P-end-labelled with T4 polynucleo-
tide kinase (N.E. Biolabs) and puri¢ed on polyacrylamide gels. EM-
SAs were performed as followed: 3 Wg of nuclear extracts were in-
cubated for 15 min at room temperature in a total volume of 20 Wl of
EMSA bu¡er (10 mM Tris^HCl (pH 7.9), 40 mM KCl, 10% glycerol,
0,05% Nonidet P-40 and 1 mM DTT) with 1 Wg poly(dI:dC) (Phar-
macia) and 1 ng of end-labelled double-stranded probes before sam-
ples were run on 4.5% acrylamide non-denaturing gels in O.25UTBE
at 22‡C and 10 V/cm. The (+) strand sequence of double-stranded




GCGG-3P). Cyc A, cdc2, cdc25C, b-myb and E2 oligonucleotides
used for competition were as previously described [4,6,10,19].
2.5. In vivo DMS genomic footprinting
In vivo DMS genomic footprinting with the LMPCR procedure
was performed essentially as described elsewhere [4,20]. 2U106 Swiss
3T3 cells per 14 cm diameter dish were treated with the guanosine
methylating agent DMS at 0.2% for 5 min at room temperature in
their cell culture medium (DMEM/FCS) bu¡ered with HEPES
(20 mM ¢nal), pH 7.4. After DMS treatment, cells were washed three
times with cold PBS/2% L-mercaptoethanol and then collected in 1 ml
of lysis bu¡er (50 mM Tris pH 8, 20 mM EDTA, 1% SDS, 2%
L-mercaptoethanol). Genomic DNA was isolated as described [4].
As a reference, genomic DNA (1 mg/ml in water) from the same
cell type was methylated in vitro with 0.5% DMS for 4 min at
room temperature. Piperidine cleavage at methylated bases was per-
formed in piperidine 1 N at 95‡C for 30 min. 2 Wg of cleaved genomic
DNA was used for LMPCR that were carried out as previously
described [4,20]. The following primers were designed to analyze the
upper strand of the transcription start site region of the mouse
p130 promoter: ASp130-1 5P-AGGCGGTGGCGACTGGTTGC-3P,
ASp130-2 5P-TTGCCTCCAGATGCCATGGC-3P and ASp130-3 5P-
TGCCTCCAGATGCCATGGCGCACC-3P. Samples were loaded
onto a 5% sequencing gel and run at 50 W. Dried gels were analyzed
with a phosphorimager from Molecular Dynamics.
3. Results and discussion
3.1. The molecular cloning of the mouse 5P £anking region of
the mouse RB2 (p130) gene reveals the presence of a
putative CDE/CHR-like element in the transcription start
site region
Searching for novel examples of CDE/CHR-like sequences
in the transcription start site region of genes encoding cell
cycle regulators, we identi¢ed in the recently cloned 5P £ank-
ing region of the human RB2 (p130) gene [21], a sequence (nt
+39^+49) resembling the CDE/CHR element of the cyclin A,
cdc2, cdc 25C, and b-myb promoters (Fig. 1C). To con¢rm the
presence of such an element and test its function we cloned
and sequenced the corresponding proximal promoter region
of the mouse p130 gene using a PCR approach with oligonu-
cleotides derived from the known mouse p130 cDNA se-
quence [17,23,24] (Fig. 1A) (GenBank Submission,
AF228064). The position of two major transcription initiation
sites was determined by primer extension (Fig. 1B). The
mouse and human p130 genes show 67% of sequence identity
in their 5P £anking regions (Fig. 1A). Both of them lack a
typical TATA box but contain several GC boxes and poten-
tial binding sites for numerous transcription factors [21]. In-
terestingly, the putative CDE/CHR-like element located near-
by one of the major transcription start sites was highly
conserved between human and mouse (Fig. 1A,B). As pro-
posed for the other previously described CDE^CHR [2], the
location of this CDE/CHR-like sequence immediately up-
stream of the initiation site raises the interesting but yet un-
proven possibility that its occupancy somehow interferes with
the process of transcriptional initiation of the p130 gene.
3.2. The CDE^CHR-like sequence is occupied by proteins in
vivo
A major feature of the CDE/CHR elements that have so far
been described is that they make major groove contacts with
proteins (G-residues contacted) which are detectable in a cel-
lular context using in vivo genomic footprinting techniques
[5^9]. Therefore, we performed an LMPCR-based genomic
footprint analysis [4,20] of the CDE/CHR region of the mouse
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p130 promoter in growing ¢broblasts using either in vivo or in
vitro DMS-methylated genomic DNA as templates (Fig. 1D).
This analysis revealed that at least four G-residues (major
groove) inside the p130 CDE/CHR sequence are protected
by proteins in vivo (Fig. 1D). This result strongly suggests
that the CDE/CHR-like sequence of the p130 gene is indeed
a functional element in vivo that makes major groove contacts
with proteins in exponentially growing mouse ¢broblasts.
3.3. Transcription of the p130 gene is strongly up-regulated
upon mutation of the CDE^CHR element
Another important feature of the previously identi¢ed
CDE/CHR elements is that inactivation of either the CDE
or the CHR leads to a signi¢cant up-regulation of promoter
activity [2]. To test whether this was also true for the p130
gene, we performed a functional analysis of the mouse p130
CDE^CHR by transiently transfecting NIH 3T3 cells with
either the wild-type or the CDE/CHR mutated versions of
p130 promoter-luciferase reporter constructs. As shown in
Fig. 2A, mutation of either the CDE or the CHR element
in the context of the p130 promoter resulted in a 15 and 20-
fold increase of the basal promoter activity, respectively, as
measured by luciferase activity in growing cells. Interestingly,
this increase was even stronger, (up to 30-fold) when cells
where transfected with a p130 reporter construct containing
mutations in both the CDE and the CHR. Altogether, the
dramatic up-regulation of promoter activity upon mutation
in either the CDE-like or the CHR-like sequence, the location
of those sequences in the transcription start site region and
Fig. 1. Promoter sequence and transcription initiation site of the
mouse p130 promoter. Identi¢cation of a putative CDE^CHR se-
quence. A: Sequence alignment between human and mouse p130
promoters. The putative CDE^CHR element is shaded. Transcrip-
tion initiation sites are indicated by a thick arrow. The thin arrow
underlining the sequence indicates the oligonucleotide used for the
primer extension assay. The numbering is relative to the ¢rst tran-
scription initiation site. B: Determination of the transcription initia-
tion site of the mouse p130 gene. Primer extension was performed
with the oligonucleotide indicated in A, using total RNAs isolated
from NIH 3T3 cells, as described in Section 2. The major extension
products are indicated by an arrow. Size standards, on the left, con-
sist of a G-ladder generated in a DMS-LMPCR in vitro footprint
reaction. C: Sequence alignments of the p130, cdc25C, b-myb, cyclin
A, cdc2, polo kinase promoter sequences in the region of the CDE
and CHR elements. Core sequences are shaded. D: In vivo foot-
print analysis of the CDE^CHR element of the mouse p130 pro-
moter. LMPCRs were performed on in vivo DMS-methylated ge-
nomic DNA templates obtained from exponentially growing Swiss
3T3 cells treated with DMS. The lane indicated as ‘in vitro’ refers
to similar LMPCR carried out with naked DNA methylated in so-
lution with DMS. Ampli¢ed DNA ladders that are visible corre-
spond to guanosines of the upper strand of the mouse p130 pro-
moter around the start site. The position of the CDE^CHR element
is shaded in the sequence. Protected residues are indicated by a
closed circle in the sequence.
Fig. 2. E¡ect of mutations within the CDE and CHR elements on
p130 promoter activity. A: Relative luciferase activities of reporter
constructs driven by either the wild-type or the CDE^CHR-mutated
versions of the p130 promoter. NIH 3T3 cells were co-transfected
either with the wild-type p130 promoter-driven luciferase reporter
vector (p130wt) or with the CDE^CHR mutated versions of the
promoter (CDEmut, CHRmut, (CDE^CHR)mut) together with A
CMV-driven L-galactosidase construct. 24 h after transfection, lucif-
erase activity was measured on exponentially growing cells and re-
sults were normalized to L-galactosidase activity. Diagram is show-
ing the average of three independent experiments. B: Relative
luciferase activities of the the wild-type and CDE^CHR mutant
p130 promoter-luciferase constructs in cells synchronized in G0 or
at the G1/S or G2-M boundaries. NIH 3T3 cells were co-transfected
either with the wild-type or with the CDE^CHR mutated p130 pro-
moter luciferase construct together with A CMV-driven L-galactosi-
dase construct. 24 h after transfection, cells were treated 18 h with
hydroxyurea to block at the G1/S transition or with nocodazole to
block in G2-M (prometaphase) or serum-starved to block in G0.
Cells were then harvested and assayed for luciferase and L-galactosi-
dase activities. Diagram is showing the average of two independent
experiments.
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their in vivo occupation by proteins in the major groove of
DNA, strongly suggest that expression of the p130 gene is
actively repressed in growing cells by a bipartite CDE^
CHR-like regulatory element.
However, while it is clear that the periodic occupation of
the CDE^CHR element in the cdc2, cdc25C, cyclin A and
B-myb promoters is responsible for the cell cycle-dependent
modulation of expression of these genes (at the G1/S or G2/M
transitions), the biological function of this element in the con-
text of the p130 gene remains to be explored. Indeed, the
measurement of the luciferase activity in cells synchronized
at various stages of the cell cycle (G0 by serum starvation
or con£uency, G1/S using hydroxyurea, G2/M using nocoda-
zole) did not reveal any signi¢cant cell cycle-dependent mod-
ulation of activity of either the wild-type p130 promoter or
CDE^CHR-mutated versions of the promoter, the later being
consistently more active than the former constructs (Fig. 2B).
Consistent with this is the fact that very little oscillation of the
level of p130 mRNA transcripts is observed in quiescent and
cycling rodent ¢broblasts ([22] ; Fajas et al., unpublished ob-
servation). Also consistent with our results is the fact that
p130 mRNAs, p130 proteins and E2F complexes containing
p130 are almost undetectable in exponentially growing cells
[1,3,15,16,22]. Thus, a possible explanation for the presence of
a permanently active repressor element in the p130 promoter
might be to maintain a low level of expression of p130 in
cycling cells. In contrast, E2F complexes containing p130 pre-
dominate in the G0 state of many di¡erentiated cells and
tissues where they are thought to play a major role in the
maintenance of the quiescent state of the cells [1,3,13]. This
correlates with a large increase in the amount of p130 protein
in these cells which might result from post-transcriptional
changes in protein stability [22] and/or from large variations
of p130 mRNA level, such as in testis during sexual matura-
tion [23] or in p19 embryonal carcinoma (EC) upon their
retinoic acid-induced di¡erentiation [17]. Although we did
not address this question in this report, our results provide
the basis and tools warranting further studies to investigate
p130 gene regulation during cell di¡erentiation and in partic-
ular to test whether this increased expression of p130 upon
di¡erentiation results from a release of the CDE^CHR-medi-
ated repression.
3.4. Characterization of the DNA^protein complexes formed on
the p130 CDE^CHR-like element
The exact composition of the protein complex(es) that bind
the various CDE^CHR repressor elements in vivo is still
highly controversial. Although it has been reported that the
CDE of the cdc2 and cyclin A promoters can bind cellular
E2F ternary complexes in vitro with low e⁄ciency [8,25] other
reports disagree with this [6,26]. Moreover, the CDE^CHR
sequence of the cdc25C promoter [19] is clearly unable to
bind E2Fs in vitro. These data appear consistent with those
suggesting that the whole CDE^CHR module in the cdc2,
cdc25C and cyclin A promoters bind e⁄ciently an unidenti¢ed
factor, named CDF1, that is clearly distinct from E2F com-
plexes and which does not associate directly with pocket pro-
teins [19,27]. More recently, it was also shown that a novel
cellular activity termed CHF (cyclin A CHR binding factor),
independent from CDF- and E2F-activities which has been
shown at present to bind only the CHR element of the cyclin
A promoter [28]. However, in the cases of CHF and CDF,
protein species carrying these activities remain to be identi¢ed.
Here, we report a preliminary characterization of the
DNA^protein complexes formed on the p130 CDE^CHR el-
ement. EMSA analyses were performed using nuclear extracts
Fig. 3. EMSAs showing a speci¢c binding of protein complexes to the p130 CDE/CHR element. A: Two di¡erent protein complexes bind the
CDE and CHR sites of the p130 promoter. Nuclear extracts from exponentially growing NIH 3T3 cells were incubated with the p130 CDE^
CHR radiolabelled oligonucleotide (lanes 1^5). Lanes 2^5 represent competition experiments with the wild-type cold oligonucleotide (lane 2) or
with oligonucleotides containing a mutation either in the CDE (lane 3) or in the CHR (lane 4) or in both the CDE and CHR (lane 5). Com-
plexes formed on either the CDE (X) or the CHR (Y) are indicated. The same nuclear extracts were also incubated with radiolabelled probes
containing a mutation in either the CDE (lane 6) or the CHR (lane 7). B: Similar protein complex(es) bind the CDE of several cell cycle-regu-
lated genes. Competition experiments using the p130 CDE^CHR probe with the same nuclear extracts as in A and a 50-fold molar excess of
the indicated cold oligonucleotides (CDE^CHR sequences of the cyclin A, cdc25C, cdc2, b-myb promoters or the consensus E2F site of the ad-
enovirus E2 promoter).
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from exponentially growing NIH-3T3 cells and a DNA probe
spanning the CDE^CHR region of the mouse p130 promoter.
At least two CDE^CHR-speci¢c retarded DNA^protein com-
plexes were detectable (Fig. 3A). Competition experiments
using a 100-fold molar excess of unlabelled oligonucleotides
containing a mutation in either the CDE or the CHR se-
quence demonstrated that the fastest and slowest migrating
complexes are speci¢c for the CHR and CDE, respectively
(Fig. 3A). The speci¢city of each of these two complexes for
either the CDE or the CHR sequence was con¢rmed by per-
forming EMSAs with DNA probes bearing mutations either
in the CDE or the contiguous CHR sequence (Fig. 3A).
We then tested whether these DNA^protein complexes
could be similar to those detected on other CDE^CHR ele-
ments. The complex formed on the CDE turned out to be
competed out by an 100-fold excess of unlabelled double
stranded oligonucleotides bearing the CDE^CHR sequence
of either the cyclin A [2,5,7] and cdc2 [2,8] promoters and,
although to a lesser extend, by the variant CDE^CHR/E2F-
DRS site of the b-myb promoter [2,9,10] (Fig. 3B). Notably,
this competing e¡ect of the cyclin A CDE^CHR for the p130
CDE-speci¢c complex depends only on the CDE sequence
since competition was still observed when the cyclin A oligo-
nucleotide was mutated within the CHR, but not if it was
mutated within its CDE sequence (Fig. 3B).
In contrast, neither an oligonucleotide bearing the CDE^
CHR of the cdc25C promoter [2,5] nor the consensus E2F
binding site of the E2 promoter [1,4] were able to interfere
with the formation of this CDE complex (Fig. 3B). Moreover,
none of these oligonucleotides was able to compete out the
CHR-speci¢c complex formed on the p130 probe (Fig. 3B).
Altogether, these EMSAs suggest not only that two di¡erent
complexes bind independently to the CDE and the CHR ele-
ments of the p130 promoter but also that the protein(s) bound
on the CDEs of p130, cyclin A and cdc2 genes might be
related, whereas di¡erent protein complexes might bind to
the CHR element.
Finally, since it has been reported that the CDE/CCRE of
the cdc2 and cyclin A promoters can bind cellular E2F ternary
complexes in vitro with low e⁄ciency [8,25] we also tested
whether E2Fs and E2F-associated proteins could be present
in the cellular complexes formed on the p130 probe. However,
neither antibodies directed against -E2F1, -E2F4, -E2F5,
-DP1, nor those directed against -pocket proteins (p107,
pRB and p130) were able to interfere with the p130 CDE
complex in EMSA (data not shown, reagents described in
reference [4]). Moreover, recombinant E2F1/DP1 and E2F4/
DP1 complexes [4] were unable to bind that probe (data not
shown) whereas they bound avidly a probe containing the
E2F site of the E2 promoter [4]. This strongly suggests that
E2F-complexes are not directly involved in the regulation of
the CDE^CHR repressor element of the p130 promoter.
The precise characterization of the protein complexes that
bind and repress these various CDE^CHR elements will be
required to further understand the molecular basis of CDE^
CHR-mediated repression.
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